![]() ![]() We believe that the simplicity of manufacturing multiplex CAR-T cells using the qCART™ system will not only significantly enhance the accessibility of CAR-T therapy but also unlock the full potential of armored CAR-T therapy for the treatment of solid tumors in the future.Įthics approval and consent to participate Fresh/frozen peripheral blood mononuclear cells (PBMCs) from adult healthy donors and patients were obtained from Chang Gung Memorial Hospital (IRB approval #201900578A3) and MacKay Memorial Hospital (IRB approval #20MMHIS330e), respectively. Importantly, we show that qCART™-manufactured CAR-T cells from hematological cancer patients expanded efficiently, effectively eradicated tumors, and can be safely controlled via an iCasp9 suicide gene-inducing drug. These cells possess all the desired attributes for ensuring therapeutic efficacy in CAR-T therapy, including high CAR-T SCM, balanced CD8/CD4 ratio, low exhaustion and senescence marker expressions, and high ex vivo and in vivo expansion capacity. ![]() What this study adds In this report, we further demonstrate in vitro and in vivo that consistent, robust, and functional iCasp9-regulatable, CD20/CD19 dual-targeted CAR-T stem cell memory (T SCM) cells can be efficiently manufactured using the qCART™ system for clinical application. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |